lansoprazole has been researched along with Diarrhea in 30 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 9.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "We herein describe a 69-year-old man suffering from chronic diarrhea caused by lansoprazole (LPZ)-induced collagenous colitis (CC) accompanied with protein-losing enteropathy (PLE), diagnosed by increased fecal alpha-1 antitrypsin clearance and the findings of leakage from the descending colon to the sigmoid colon on scintigraphy." | 7.88 | Evaluation by MR Enterocolonography of Lansoprazole-induced Collagenous Colitis Accompanied with Protein-losing Enteropathy. ( Furuhashi, H; Higashiyama, M; Hokari, R; Ikeyama, K; Komoto, S; Maruta, K; Miura, S; Mizoguchi, A; Nagao, S; Nishii, S; Shirakabe, K; Takajo, T; Terada, H; Tomita, K; Watanabe, C; Yasutake, Y, 2018) |
| "We report a case of a 75-year-old woman with urgent watery diarrhea, occurring 5 to 8 times per day, which began after starting lansoprazole (30 mg/day) for erosive gastritis." | 7.78 | [A case of collagenous colitis with watery diarrhea due to lansoprazole use in an elderly woman]. ( Akishita, M; Honda, M; Ota, H; Ouchi, Y; Yamaguchi, Y, 2012) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 7.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "A case of severe diarrhea and hypergastrinemia after 6 wk of lansoprazole therapy is presented." | 7.70 | Lansoprazole: a cause of secretory diarrhea. ( Goff, JS, 1998) |
| "We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks." | 7.70 | [lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 5.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| "Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events." | 5.31 | Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002) |
| "Five patients with gastroesophageal reflux disease (GERD), who also had chronic functional diarrhea and postprandial urgency, unexpectedly noted rapid relief of their diarrhea and urgency when they took lansoprazole for their heartburn." | 5.09 | Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea. ( Dave, B; Rubin, W, 1999) |
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 5.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| " pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone." | 5.08 | Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. ( Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A, 1996) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| "Although bismuth was both the first drug shown to alter the natural history of peptic ulcer disease and also a constituent of the first very effective eradication regimens, it has been excluded from the newer regimens, despite its safety and low cost, in favour of two antibiotics." | 5.08 | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. ( Scott, BB, 1998) |
| " The most common adverse events of headache, diarrhea, and nausea have been reported in fewer than 5% of patients treated with lansoprazole or omeprazole." | 4.80 | Safety profile of the proton-pump inhibitors. ( Reilly, JP, 1999) |
| "We herein describe a 69-year-old man suffering from chronic diarrhea caused by lansoprazole (LPZ)-induced collagenous colitis (CC) accompanied with protein-losing enteropathy (PLE), diagnosed by increased fecal alpha-1 antitrypsin clearance and the findings of leakage from the descending colon to the sigmoid colon on scintigraphy." | 3.88 | Evaluation by MR Enterocolonography of Lansoprazole-induced Collagenous Colitis Accompanied with Protein-losing Enteropathy. ( Furuhashi, H; Higashiyama, M; Hokari, R; Ikeyama, K; Komoto, S; Maruta, K; Miura, S; Mizoguchi, A; Nagao, S; Nishii, S; Shirakabe, K; Takajo, T; Terada, H; Tomita, K; Watanabe, C; Yasutake, Y, 2018) |
| "We report a case of a 75-year-old woman with urgent watery diarrhea, occurring 5 to 8 times per day, which began after starting lansoprazole (30 mg/day) for erosive gastritis." | 3.78 | [A case of collagenous colitis with watery diarrhea due to lansoprazole use in an elderly woman]. ( Akishita, M; Honda, M; Ota, H; Ouchi, Y; Yamaguchi, Y, 2012) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 3.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "A case of severe diarrhea and hypergastrinemia after 6 wk of lansoprazole therapy is presented." | 3.70 | Lansoprazole: a cause of secretory diarrhea. ( Goff, JS, 1998) |
| "We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks." | 3.70 | [lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000) |
| " Side-effect profile and tolerability were assessed using a symptom-based questionnaire." | 2.73 | Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. ( Cindoruk, M; Dursun, A; Erkan, G; Karakan, T; Unal, S, 2007) |
| "Metronidazole resistance was induced in 8 out of 16 with a sensitive strain." | 2.68 | One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. ( de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ, 1997) |
| "Lansoprazole can cause MC." | 2.47 | Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. ( Attilia, F; Capurso, G; Colarossi, C; Delle Fave, G; Di Giulio, E; Marignani, M; Milione, M; Zampaletta, C, 2011) |
| "Omeprazole was used in 90% of the patients; lansoprazole, in 7%." | 1.34 | Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. ( El-Serag, HB; Hassall, E; Kerr, W, 2007) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 1.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| "Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events." | 1.31 | Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002) |
| "To estimate the rates of common adverse events in patients treated with the proton pump inhibitors omeprazole, lansoprazole and pantoprazole in general practice in England." | 1.31 | The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. ( Dunn, NR; Freemantle, S; Martin, RM; Shakir, S, 2000) |
| "Lansoprazole was mostly prescribed in patients with reflux oesophagitis (55." | 1.30 | A prospective follow-up study of 5669 users of lansoprazole in daily practice. ( Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (33.33) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 7 (23.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mizoguchi, A | 1 |
| Higashiyama, M | 1 |
| Ikeyama, K | 1 |
| Nishii, S | 1 |
| Terada, H | 1 |
| Furuhashi, H | 1 |
| Takajo, T | 1 |
| Maruta, K | 1 |
| Yasutake, Y | 1 |
| Shirakabe, K | 1 |
| Watanabe, C | 1 |
| Tomita, K | 1 |
| Komoto, S | 1 |
| Nagao, S | 1 |
| Miura, S | 1 |
| Hokari, R | 1 |
| Shiratori, Y | 1 |
| Fukuda, K | 1 |
| Ota, H | 1 |
| Honda, M | 1 |
| Yamaguchi, Y | 1 |
| Akishita, M | 1 |
| Ouchi, Y | 1 |
| Konijeti, GG | 1 |
| Deshpande, V | 1 |
| Bunker, CJ | 1 |
| Bardet, R | 1 |
| Moreno, JP | 1 |
| Rodriguez, T | 1 |
| Trémeau, AL | 1 |
| Hernandez, É | 1 |
| Bolot, AL | 1 |
| Kovacs, TO | 1 |
| Freston, JW | 1 |
| Haber, MM | 1 |
| Hunt, B | 1 |
| Atkinson, S | 1 |
| Peura, DA | 1 |
| Sasatomi, Y | 1 |
| Takahata, M | 1 |
| Abe, Y | 1 |
| Ishimura, A | 1 |
| Miyake, K | 1 |
| Ogahara, S | 1 |
| Murata, T | 1 |
| Nakashima, H | 1 |
| Maeda, K | 1 |
| Saito, T | 1 |
| Capurso, G | 1 |
| Marignani, M | 1 |
| Attilia, F | 1 |
| Milione, M | 1 |
| Colarossi, C | 1 |
| Zampaletta, C | 1 |
| Di Giulio, E | 1 |
| Delle Fave, G | 1 |
| Thomson, RD | 1 |
| Lestina, LS | 1 |
| Bensen, SP | 1 |
| Toor, A | 1 |
| Maheshwari, Y | 1 |
| Ratcliffe, NR | 1 |
| Claessens, AA | 1 |
| Heerdink, ER | 1 |
| van Eijk, JT | 1 |
| Lamers, CB | 2 |
| Leufkens, HG | 1 |
| Mukherjee, S | 1 |
| Rammer, M | 1 |
| Kirchgatterer, A | 1 |
| Höbling, W | 1 |
| Knoflach, P | 1 |
| Hilmer, SN | 1 |
| Heap, TR | 1 |
| Eckstein, RP | 1 |
| Lauer, CS | 1 |
| Shenfield, GM | 1 |
| Hassall, E | 1 |
| Kerr, W | 1 |
| El-Serag, HB | 1 |
| Cindoruk, M | 1 |
| Erkan, G | 1 |
| Karakan, T | 1 |
| Dursun, A | 1 |
| Unal, S | 1 |
| Gough, AL | 1 |
| Long, RG | 1 |
| Cooper, BT | 1 |
| Fosters, CS | 1 |
| Garrett, AD | 1 |
| Langworthy, CH | 1 |
| de Boer, WA | 1 |
| van Etten, RJ | 1 |
| Schade, RW | 1 |
| Ouwehand, ME | 1 |
| Schneeberger, PM | 1 |
| van Unnik, AJ | 1 |
| Tytgat, GN | 1 |
| Leufkens, H | 1 |
| Claessens, A | 1 |
| Heerdink, E | 1 |
| van Eijk, J | 1 |
| Harford, W | 1 |
| Lanza, F | 1 |
| Arora, A | 1 |
| Graham, D | 1 |
| Haber, M | 2 |
| Weissfeld, A | 2 |
| Rose, P | 2 |
| Siepman, N | 2 |
| Schwartz, H | 1 |
| Krause, R | 1 |
| Kidd, S | 1 |
| Sahba, B | 1 |
| O'Connor, HJ | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Cunnane, K | 1 |
| Scott, BB | 1 |
| Goff, JS | 1 |
| Dave, B | 1 |
| Rubin, W | 1 |
| Reilly, JP | 1 |
| Richter, JE | 1 |
| Campbell, DR | 1 |
| Kahrilas, PJ | 1 |
| Huang, B | 1 |
| Fludas, C | 1 |
| Martin, RM | 1 |
| Dunn, NR | 1 |
| Freemantle, S | 1 |
| Shakir, S | 1 |
| Ghilain, JM | 1 |
| Schapira, M | 1 |
| Maisin, JM | 1 |
| De Maeght, S | 1 |
| Piron, A | 1 |
| Gerard, R | 1 |
| Henrion, J | 1 |
| Lau, CF | 1 |
| Hui, PK | 1 |
| Fung, TT | 1 |
| Tung, SY | 1 |
| Wong, AM | 1 |
| Loo, CK | 1 |
| Lam, KM | 1 |
| Miwa, H | 1 |
| Kurosawa, A | 1 |
| Sato, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753] | Phase 4 | 143 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lansoprazole and Diarrhea
| Article | Year |
|---|---|
Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Aged; Aged, 80 and over; Anti-Ulcer Agents; | 2011 |
Safety profile of the proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Diarrhea; Drug Interactions; Gastric Muc | 1999 |
[Adverse effects of H. pylori eradication therapy and its measure].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Diarrhea; Drug Therap | 2002 |
10 trials available for lansoprazole and Diarrhea
| Article | Year |
|---|---|
Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Diarrhea; D | 2009 |
Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Diarrhea; Double- | 2007 |
Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diarrhea; Double-Blind Method; Enzyme Inhibitors; Esophagit | 1996 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1997 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diar | 1996 |
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration | 1996 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; | 1998 |
Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Chronic Disease; Colonic Disea | 1999 |
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Antacids; A | 2000 |
17 other studies available for lansoprazole and Diarrhea
| Article | Year |
|---|---|
Evaluation by MR Enterocolonography of Lansoprazole-induced Collagenous Colitis Accompanied with Protein-losing Enteropathy.
Topics: Aged; Colitis, Collagenous; Diarrhea; Humans; Lansoprazole; Magnetic Resonance Imaging; Male; Protei | 2018 |
Collagenous colitis diagnosed by endoscopically induced mucosal tears.
Topics: Aged; Chronic Disease; Colitis, Collagenous; Colon; Diarrhea; Endoscopy, Digestive System; Humans; I | 2019 |
[A case of collagenous colitis with watery diarrhea due to lansoprazole use in an elderly woman].
Topics: Aged; Colitis, Collagenous; Diarrhea; Female; Humans; Lansoprazole; Proton Pump Inhibitors | 2012 |
An unusual case of chronic diarrhea. Lansoprazole-induced microscopic colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Biopsy, Needle; Chronic Disease; Colitis | 2013 |
[A resistant diarrhea].
Topics: Aged, 80 and over; Anti-Ulcer Agents; Antidepressive Agents; Antidiarrheals; Colitis; Comorbidity; D | 2016 |
[Case of suspicious lansoprazole-associated collagenous colitis in ANCA-associated nephritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Antibodies, Antineutrophil Cytopla | 2010 |
Lansoprazole-associated microscopic colitis: a case series.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Colitis; Co | 2002 |
Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Infective Agents; Child; Chil | 2002 |
Diarrhea associated with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Colonoscopy; Diarrhea; Gastroin | 2003 |
Lansoprazole-associated collagenous colitis: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differen | 2005 |
Microscopic colitis associated with exposure to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Biopsy; Chronic Disease; Colitis, Collagenous; Coliti | 2006 |
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Distribution; Child; Child, Preschool; Cohort Studies; | 2007 |
A prospective follow-up study of 5669 users of lansoprazole in daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1997 |
Lansoprazole: a cause of secretory diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Diarrhea; Femal | 1998 |
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Adverse Drug Reaction Reporting Syst | 2000 |
[lymphocytic colitis associated with lansoprazole treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Diarrhea; Humans; Intestinal Mu | 2000 |
Pseudomembranous colitis without diarrhoea following Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2001 |